Home Cart Sign in  
Chemical Structure| 856676-23-8 Chemical Structure| 856676-23-8

Structure of Choline Fenofibrate
CAS No.: 856676-23-8

Chemical Structure| 856676-23-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Choline fenofibrate is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia.

Synonyms: ABT-335

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Choline Fenofibrate

CAS No. :856676-23-8
Formula : C22H28ClNO5
M.W : 421.91
SMILES Code : O=C(C1=CC=C(OC(C)(C([O-])=O)C)C=C1)C2=CC=C(Cl)C=C2.C[N+](C)(CCO)C
Synonyms :
ABT-335
MDL No. :MFCD18382233
InChI Key :JWAZHODZSADEHB-UHFFFAOYSA-M
Pubchem ID :11350701

Safety of Choline Fenofibrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Choline Fenofibrate (ABT-335), the choline salt of Fenofibric acid, releases Fenofibric acid in the gastrointestinal tract, activating PPAR with antihyperlipidemic effects[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01211847 Hypertriglyceridemia ... More >> Dyslipidemia Less << Phase 2 Completed - -
NCT00639158 Dyslipidemias ... More >> Coronary Heart Disease Combined (Atherogenic) Dyslipidemia Mixed Dyslipidemia Less << Phase 3 Completed - -
NCT00639158 - Completed - -
NCT03382756 Dyslipidemias Phase 1 Completed - Korea, Republic of ... More >> Dong-A University Hospital Busan, Seo-gu, Korea, Republic of, 602-812 Less <<
NCT00616772 Coronary Artery Disease ... More >> Coronary Heart Disease Dyslipidemia Less << Phase 3 Completed - -
NCT03346187 Dyslipidemias Phase 1 Completed - Korea, Republic of ... More >> Dong-A University Hospital Busan, Seo-gu, Korea, Republic of, 602-812 Less <<
NCT00683176 Diabetic Macular Edema Phase 2 Completed - Bulgaria ... More >> Site Reference ID/Investigator# 54268 Sofia, Bulgaria, 1000 Site Reference ID/Investigator# 54291 Sofia, Bulgaria, 1233 Site Reference ID/Investigator# 54279 Sofia, Bulgaria, 1408 Site Reference ID/Investigator# 54273 Sofia, Bulgaria, 1517 Czech Republic Site Reference ID/Investigator# 54267 Brno, Czech Republic, 62500 Site Reference ID/Investigator# 54282 Ostrava-Vitkovice, Czech Republic, 703 84 Site Reference ID/Investigator# 54283 Prague, Czech Republic, 169 02 Site Reference ID/Investigator# 54270 Usti nad Labem, Czech Republic, 40113 Denmark Site Reference ID/Investigator# 54274 Glostrup, Denmark, 2600 Germany Site Reference ID/Investigator# 54263 Leipzig, Germany, 04103 Site Reference ID/Investigator# 54284 Muenster, Germany, 48145 Hungary Site Reference ID/Investigator# 54269 Budapest, Hungary, 1106 Site Reference ID/Investigator# 54277 Gyor, Hungary, H-9023 Site Reference ID/Investigator# 54275 Zalaegerszeg - Pozva, Hungary, 8900 Italy Site Reference ID/Investigator# 54272 Udine, Italy, 33100 Netherlands Site Reference ID/Investigator# 54293 Amsterdam, Netherlands, 1105 AZ Poland Site Reference ID/Investigator# 54265 Gdansk, Poland, 80-147 Site Reference ID/Investigator# 54266 Katowice, Poland, 40-760 Spain Site Reference ID/Investigator# 54280 Madrid, Spain, 28002 Site Reference ID/Investigator# 54264 Santiago de Compostela, Spain, 15705 United Kingdom Site Reference ID/Investigator# 54271 Liverpool, United Kingdom, L7 8XP Less <<
NCT00673881 Dyslipidemia Phase 1 Phase 2 Completed - United States, Illinois ... More >> Radiant Research, 515 N State St, #2700 Chicago, Illinois, United States, 60610 Less <<
NCT00616772 - Completed - -
NCT00673881 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.85mL

2.37mL

1.19mL

23.70mL

4.74mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories